Cost Advantages of Single-Use Technologies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Cost Advantages of Single-Use Technologies
Single-use technologies can help simplify equipment and facility design, thus bringing cost advantages. But how are these cost advantages realized and what criteria can be used to assess their impact? This article is part of a special issue on Bioprocessing and Sterile Manufacturing.


Pharmaceutical Technology
Volume 34, pp. s26-s31

Environment and waste

The idea of discarding plastic bags appears intuitively wasteful, but disposal must be compared with traditional technology that requires cleaning and sterilization between batches. Recent studies estimate that single-use technology is 25–50% less carbon-dioxide intensive than is stainless steel (3, 4). Consuming and heating large volumes of water to clean and sterilize stainless-steel equipment is more energy demanding than producing and inactivating plastic bags, which can also be incinerated for energy recovery. Sinclair and colleagues notably demonstrated that automobile emissions from facility staff's daily commute were the overwhelming contributors to carbon-dioxide emissions (3).

The typical approach to solid waste disposal is to deactivate locally and then physically dispose of single-use equipment in an incinerator or landfill. As the amount of solid waste increases, waste storage, deactivation autoclave capacities, and transportation may be limited by the facility's physical boundaries. Depending on policies for the transport of material potentially containing live genetically modified organisms and process-containment requirements, an alternative is to handle solid waste as hospital waste and postpone the investment in deactivation capacity. The waste is then subject to stricter control and visual markings. A specialized vehicle takes the waste to a power plant (off- or on-site) for incineration, where some of the energy used to produce the plastic film is recaptured. Costs for this strategy can amount to about $100/metric ton of waste. The volume also affects the cost because of the number of trips necessary. This cost is relatively low because one could avoid installing a deactivation autoclave, although one must factor in the cost for additional handling. In one example, NNE Pharmaplan calculated that off-site incineration would enable production for five years before accumulated running costs outweighed the cost of investing in an autoclave.

Conclusion

The new single-use production paradigm shifts quality away from in-facility testing to supplier auditing and storage costs. These activities mainly take place before the equipment enters the production facility. Quality costs and waste costs are still not well described, but future work on the cost advantages of single-use technologies will address these aspects to a larger extent.

Niels Guldager is a senior consultant for bioprocess and technology at NNE Pharmaplan, Vandtarnsvej 108–110, 2860 Soborg, Denmark, tel. +45 3079 7246, fax +45 4444 3777,
.

References

1. N. Guldager, "Economic Drivers for Implementation of Single-Use Technology" (whitepaper, NNE Pharmaplan, Soborg, Denmark) in press, 2010.

2. B. Barnoon and B. Bader, BioPharm Int. Nov. supplement, "Guide to Disposables," 30–43 (2008).

3. A. Sinclair et al., BioPharm Int. Nov. supplement, "Guide to Disposables," 4–15 (2008).

4. B. Rawlings and H. Pora, BioProc. Int. 7 (2), 18–26 (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here